MRS 2500 tetraammonium salt
Cat. No. 2159
Chemical Name: (1R*,2S*)-4-[2-Iodo-6-(methylamino)
Biological ActivityHighly potent and selective antagonist of the platelet P2Y1 receptor (Ki = 0.78 nM). Inhibits ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Inhibits the upregulation of NTPDase1 by ATPγS. Prevents thrombus formation in vivo.
Licensing InformationSold under license from the NIH, US Patent 10/169975
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Kim et al (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J.Med.Chem 46 4974. PMID: 14584948.
Cattaneo et al (2004) Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor. Biochem.Pharmacol. 68 1995. PMID: 15476670.
Hechler et al (2006) MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3', 5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J.Pharmacol.Exp.Ther. 316 556. PMID: 16236815.
Lu et al (2007) Stimulation of the P2Y1 receptor up-regulates nucleoside-triphosphate diphosphohydrolase-1 in human retinal pigment epithelial cells. J.Pharmacol.Exp.Ther. 323 157. PMID: 17626796.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: MRS 2500 tetraammonium salt, supplier, potent, selective, P2Y1, antagonists, Receptors, Purinergic, purinoceptors, MRS2500, prevents, thrombus, formation
Find multiple products by catalog number
New Products in this Area
High affinity and selective EP4 antagonistTCS 3035
GPR35 agonistPF 5274857 hydrochloride
Potent and selective smoothened (Smo) receptor antagonistGSK 137647
Potent and selective FFA4 (GPR120) agonistAH 7614
Selective FFA4 (GPR120) antagonistProsaptide TX14(A)
Potent GPR37 and GPR37L1 agonist
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.